Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Ruck, TobiasBock, Stefanie
Pfeuffer, Steffen
Schroeter, Christina B
Cengiz, Derya
Marciniak, Paul
Lindner, Maren
Herrmann, Alexander
Liebmann, Marie
Kovac, Stjepana
Gola, Lukas
Rolfes, Leoni
Pawlitzki, Marc
Opel, Nils
Hahn, Tim
Dannlowski, Udo
Pap, Thomas
Luessi, Felix
Schreiber, Julian A
Wünsch, Bernhard
Kuhlmann, Tanja
Seebohm, Guiscard
Tackenberg, Björn
Seja, Patricia
Döring, Frank
Wischmeyer, Erhard
Chasan, Achmet Imam
Roth, Johannes
Klotz, Luisa
Meyer Zu Hörste, Gerd
Wiendl, Heinz
Marschall, Tobias
Floess, Stefan
Huehn, Jochen
Budde, Thomas
Bopp, Tobias
Bittner, Stefan
Meuth, Sven G
Issue Date
2021-10-26
Metadata
Show full item recordAbstract
It remains largely unclear how thymocytes translate relative differences in T cell receptor (TCR) signal strength into distinct developmental programs that drive the cell fate decisions towards conventional (Tconv) or regulatory T cells (Treg). Following TCR activation, intracellular calcium (Ca2+) is the most important second messenger, for which the potassium channel K2P18.1 is a relevant regulator. Here, we identify K2P18.1 as a central translator of the TCR signal into the thymus-derived Treg (tTreg) selection process. TCR signal was coupled to NF-κB-mediated K2P18.1 upregulation in tTreg progenitors. K2P18.1 provided the driving force for sustained Ca2+ influx that facilitated NF-κB- and NFAT-dependent expression of FoxP3, the master transcription factor for Treg development and function. Loss of K2P18.1 ion-current function induced a mild lymphoproliferative phenotype in mice, with reduced Treg numbers that led to aggravated experimental autoimmune encephalomyelitis, while a gain-of-function mutation in K2P18.1 resulted in increased Treg numbers in mice. Our findings in human thymus, recent thymic emigrants and multiple sclerosis patients with a dominant-negative missense K2P18.1 variant that is associated with poor clinical outcomes indicate that K2P18.1 also plays a role in human Treg development. Pharmacological modulation of K2P18.1 specifically modulated Treg numbers in vitro and in vivo. Finally, we identified nitroxoline as a K2P18.1 activator that led to rapid and reversible Treg increase in patients with urinary tract infections. Conclusively, our findings reveal how K2P18.1 translates TCR signals into thymic T cell fate decisions and Treg development, and provide a basis for the therapeutic utilization of Treg in several human disorders.Citation
Cell Res. 2022 Jan;32(1):72-88. doi: 10.1038/s41422-021-00580-z. Epub 2021 Oct 26. PMID: 34702947.Affiliation
HZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.Publisher
Springer NatureJournal
Cell researchPubMed ID
34702947Type
ArticleLanguage
enEISSN
1748-7838ae974a485f413a2113503eed53cd6c53
10.1038/s41422-021-00580-z
Scopus Count
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-ShareAlike 4.0 International